YM BioSciences reports nimotuzumab approved for marketing in Mexico
YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico .
MedImmune today announced that the US Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.